Tyrosine kinase inhibitors (TKIs) elicit high response rates among individuals with kinase-driven
malignancies, including chronic myeloid leukemia (CML) and epidermal growth factor …

Purpose: EML4-ALK is a lung cancer oncogene, and ALK inhibitors show marked therapeutic
efficacy for tumors harboring this fusion gene. It remains unsettled, however, how the …

Background and objective: To clarify the clinical characteristics and risk factors for acute
respiratory deterioration following anti‐cancer therapy in patients with pulmonary fibrosis (PF) …

Background and objective The results of studies examining the outcome and the factors
predicting prognosis in combined pulmonary fibrosis and emphysema ( CPFE ) have so far been …

Background: Germline alterations in the proapoptotic protein Bcl-2–like 11 (BIM) can have a
crucial role in tumor response to treatment. To determine the clinical utility of detecting BIM …

Background and objective Treatment with pirfenidone may slow the decline in vital capacity
and increase progression‐free survival ( PFS ) in idiopathic pulmonary fibrosis ( IPF ). The …

A ciliated muconodular papillary tumor has been reported to be a peripheral low-grade
malignant tumor, consisting of ciliated columnar cells and goblet cells with basaloid cell …

Aim: This pilot study assessed correlations between circulating tumor cells (CTCs) and circulating
free DNA (cfDNA) of metastatic non-small cell lung cancer (NSCLC) after acquisition of …

Long non‑coding RNAs (lncRNAs) have been reported to be involved in the physiological
and pathological processes of tumor pathogenesis, including epithelial‑mesenchymal …

Objective To assess the efficacy of pirfenidone in patients with advanced-stage idiopathic
pulmonary fibrosis (IPF), we conducted a retrospective study of patients who received …